Agios Pharmaceuticals Quarterly Balance Sheet
NASDAQ: AGIOHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Agios Pharmaceuticals financial position
As of Jun 30, 2026, Agios Pharmaceuticals reported total assets of $1.11 billion, down 24.7% from a year earlier against total liabilities of $82.4 million. Shareholders' equity stood at $1.03 billion, or 92.6% of assets. The company held $99.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.22, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Agios Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 99.65M | 113.60M | 89.13M | 92.71M | 80.87M | 78.96M | 76.25M | 253.73M | 84.52M | 118.76M | 88.20M | 64.33M |
| Short-Term Investments | 517.93M | 623.44M | 765.29M | 860.15M | 858.07M | 814.41M | 817.46M | 751.03M | 485.37M | 479.23M | 688.72M | 583.15M |
| Inventory | 35.75M | 35.09M | 32.92M | 32.03M | 30.85M | 29.61M | 27.62M | 26.43M | 23.94M | 23.07M | 19.08M | 17.27M |
| Total Current Assets | 717.67M | 834.84M | 942.05M | 1.03B | 1.02B | 968.62M | 965.60M | 1.07B | 632.13M | 663.63M | 833.84M | 704.35M |
| Property, Plant & Equipment | 9.95M | 10.57M | 10.78M | 10.68M | 10.58M | 11.07M | 11.68M | 11.82M | 12.73M | 14.12M | 15.38M | 16.79M |
| Long-Term Investments | 347.25M | 308.45M | 310.01M | 304.34M | 400.47M | 531.25M | 638.32M | 655.89M | 75.40M | 116.30M | 29.43M | 224.90M |
| Total Assets | 1.11B | 1.18B | 1.30B | 1.39B | 1.47B | 1.56B | 1.66B | 1.79B | 773.06M | 849.71M | 937.12M | 1.01B |
| Accounts Payable | 16.34M | 13.75M | 18.36M | 19.55M | 17.53M | 13.73M | 16.64M | 17.14M | 10.04M | 11.15M | 9.78M | 13.27M |
| Total Current Liabilities | 70.22M | 58.84M | 82.21M | 74.76M | 70.41M | 52.37M | 81.16M | 119.45M | 62.64M | 51.69M | 67.95M | 58.42M |
| Total Liabilities | 82.40M | 75.88M | 104.11M | 101.38M | 101.68M | 88.99M | 122.24M | 165.12M | 112.55M | 105.79M | 126.10M | 120.42M |
| Shareholders' Equity | 1.03B | 1.11B | 1.19B | 1.28B | 1.37B | 1.47B | 1.54B | 1.63B | 660.51M | 743.92M | 811.02M | 886.84M |
| Retained Earnings | -761.52M | -660.82M | -561.71M | -453.67M | -350.23M | -238.21M | -148.92M | -52.40M | -1.00B | -904.20M | -822.65M | -726.71M |
| Net Cash (Debt) | 617.58M | 737.04M | 854.42M | 952.86M | 938.94M | 893.38M | 893.71M | 1.00B | 569.89M | 597.99M | 776.93M | 647.49M |
| Shares Outstanding | 59.60M | 59.34M | 58.45M | 58.28M | 58.04M | 57.89M | 57.16M | 57.02M | 56.88M | 56.75M | 55.95M | 55.88M |
This table shows 12 quarterly periods of Agios Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow AGIO's reporting calendar. What is a balance sheet?